Rallybio Corporation
NASDAQ:RLYBBiotechnology
+$0.01 today
- Market cap
- $82.16M
- Beta
- -0.88
- P/E (TTM)
- -11.6
- EPS (TTM)
- -$1.37
Volume 0.03M
Average 0.25M
RLYB EBITDA
Earnings before interest, taxes, depreciation, and amortization; a proxy for operating profit before non-cash and financing charges.
Rallybio CorporationNASDAQ: RLYB
EBITDA · Q1 FY2026 · quarter ended Mar 2026
EBITDA remains negative
Q1 FY2026 EBITDA was -$4.73M, compared with -$9.64M a year earlier. Trailing-twelve-month EBITDA was -$28.06M.
Context
- EBITDA amounted to 3260.1% of revenue in FY2025, down 6231.2 pp from a year earlier.
- EBITDA grew in size in 1 of the last 3 fiscal years.
- FY2025 was the smallest annual figure in the 4 fiscal years shown.
What to watch
Whether EBITDA reaches the consensus estimate from 1 analysts of -$31M (-10.8%) for the fiscal year ending Dec 2026, a slowdown from the +53.7% reported in FY2025.
Sources:Income Statement Analyst consensus estimates Text generated from reported figures; not investment advice.
- Latest quarterMar 2026
- -$4.73M+26.2% QoQ
- Last fiscal yearDec 2025
- -$27.97M+53.7% YoY
- LTMMar 2026
- -$28.06M+44.2% YoY
| Horizon | Past | Forecast | Difference |
|---|---|---|---|
| Quarter | +50.9% | — | — |
| 1 year | +53.7% | -10.8% | -64.5 pp |
| 3-year CAGR | — | — | — |
| 5-year CAGR | — | — | |
| 10-year CAGR | — | — |
Forecasts compare the consensus estimate with the latest reported period. Difference is forecast minus past, in percentage points.
EBITDA history
USD · from the income statement
- Latest · FY2025
- (27.97M) USD
- Year-over-year change
- +53.7%
| Period | Period end | EBITDA | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | (27.97M) | +53.7% |
| FY2024 | 2024-12-31 | (60.37M) | +23.4% |
| FY2023 | 2023-12-31 | (78.78M) | -16.3% |
| FY2022 | 2022-12-31 | (67.72M) | -49.2% |
| FY2021 | 2021-12-31 | (45.39M) | — |
EBITDA vs competitors
How RLYB compares with its peers on the latest reported figures
- RLYB's LTM Mar 2026 EBITDA of -$28.06M is the 2nd highest of the 4 companies compared; the peer median is -$32.35M.
- Its year-over-year change of +44.2% is the 2nd highest of 4, against a peer median of +15.1%.
- EBITDA amounts to 3270.4% of revenue for RLYB, versus a peer median of 16193.1%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Mar 2026 | $22.15M | +154.8% | — | 41.2% | |
| LTM Mar 2026 | -$28.06M | +44.2% | — | 3270.4% | |
| LTM Jun 2026 | -$32.35M | -89.8% | — | 32345.0% | |
| LTM Mar 2026 | -$54.78M | +15.1% | — | — | |
| Peer median (excluding RLYB) | -$32.35M | +15.1% | — | 16193.1% | |
Competitors are the stored peer set for RLYB. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Income Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Revenue | 0 | 0 | 0 | 636K | 858K |
| Cost of Revenue | 109K | 167K | 150K | 131K | 92K |
| Gross Profit | (109K) | (167K) | (150K) | 636K | 766K |
| Gross Margin | — | — | — | 100.0% | 89.3% |
| Research & Development | 26.91M | 40.69M | 53.54M | 41.51M | 19.6M |
| Selling, General & Admin | 18.74M | 27.2M | 25.39M | 19.63M | 14.33M |
| Operating Expenses | 45.65M | 67.88M | 78.93M | 61.13M | 28.83M |
| Depreciation & Amortization | 109K | 167K | 150K | 131K | 92K |
| EBITDA | (45.39M) | (67.72M) | (78.78M) | (60.37M) | (27.97M) |
| EBITDA Margin | — | — | — | -9491.4% | -3260.1% |
| Operating Income | (45.65M) | (67.88M) | (78.93M) | (60.5M) | (28.06M) |
| Operating Margin | — | — | — | -9511.9% | -3270.9% |
| Interest Income | 54K | 1.96M | 6.15M | 4.22M | 2.19M |
| Interest Expense | 10K | 0 | 0 | 0 | 0 |
| Other Income / Expenses | (1.37M) | 1.23M | 4.37M | 2.72M | 19.09M |
| Income Before Tax | (47.01M) | (67.73M) | (74.56M) | (57.78M) | (8.98M) |
| Pre-Tax Margin | — | — | — | -9084.1% | -1046.4% |
| Income Tax Expense | 0 | (1.08M) | 0 | 0 | 0 |
| Net Income | (47.01M) | (66.65M) | (74.56M) | (57.78M) | (8.98M) |
| Net Margin | — | — | — | -9084.1% | -1046.4% |
| EPS (Basic) | (11.68) | (16.72) | (14.72) | (10.64) | (1.59) |
| EPS (Diluted) | (11.68) | (16.72) | (14.72) | (10.64) | (1.59) |
| Weighted Avg Shares | 4.02M | 3.98M | 5.06M | 5.44M | 5.63M |
| Weighted Avg Shares (Diluted) | 4.02M | 3.98M | 5.06M | 5.44M | 5.63M |
Rallybio Corporation
NASDAQ:RLYB
Intrinsic Alpha fair value
Locked
Current Price
$15.26
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.